Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012066331 - CROSS PROTECTIVE EPITOPES OF ASPERGILLUS FUMIGATUS AND CANDIDA ALBICANS

Publication Number WO/2012/066331
Publication Date 24.05.2012
International Application No. PCT/GB2011/052239
International Filing Date 16.11.2011
IPC
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/725 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
G01N 33/569 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
A61P 31/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
10Antimycotics
CPC
A61K 2039/52
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
52Bacterial cells; Fungal cells; Protozoal cells
A61K 2039/542
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
54characterised by the route of administration
541Mucosal route
542oral/gastrointestinal
A61K 2039/543
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
54characterised by the route of administration
541Mucosal route
543intranasal
A61K 39/0002
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
0002Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
A61P 31/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
10Antimycotics
C07K 14/38
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
37from fungi
38from Aspergillus
Applicants
  • CELL MEDICA LTD [GB]/[GB] (AllExceptUS)
  • TOPP, Max, S [DE]/[DE] (UsOnly)
  • STUEHLER, Claudia [DE]/[DE] (UsOnly)
  • KHANNA, Nina [CH]/[CH] (UsOnly)
Inventors
  • TOPP, Max, S
  • STUEHLER, Claudia
  • KHANNA, Nina
Agents
  • MILES, John, Stephen
Priority Data
1019437.117.11.2010GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CROSS PROTECTIVE EPITOPES OF ASPERGILLUS FUMIGATUS AND CANDIDA ALBICANS
(FR) ÉPITOPES DE PROTECTION CROISÉE D'ASPERGILLUS FUMIGATUS ET CANDIDA ALBICANS
Abstract
(EN)
A complex comprising a Class II HLA-DRB1*03 or Class II HLA-DRB1*13 molecule bound to a peptide, wherein the peptide comprises the amino acid sequence HTYTIDWTKDAVTWS or a portion thereof, or a variant of the given amino acid sequence or portion wherein the side chains of one or two or three or four or five or six or seven of the amino acid residues are altered, wherein the peptide comprising the portion, or variant, is capable of binding HLA-DRB1*03 and/or HLA-DRB1*13. The complex may be used to select Aspergillus and Candida antigen-specific T cells. A vaccine against Candida albicans infection comprising (a) a peptide comprising the amino acid sequence HTYTIDWTKDAVTWS or a portion thereof, or a variant of the given amino acid sequence or portion wherein the side chains of one or two or three or four or five or six or seven of the amino acid residues are altered, wherein the peptide comprising the portion, or variant, is capable of binding HLA-DRB1*03 and/or HLA-DRB1*04 and/or HLA-DRB1*13, or (b) a polypeptide which is a fusion of any of the peptides of (a) and another peptide, or (c) a polynucleotide encoding a peptide of (a) or a polypeptide of (b) or (d) an expression vector capable of expressing a peptide of (a) or a polypeptide of (b). A peptide of less than 10 000 molecular weight comprising the amino acid sequence HTYTIDWTKDAVTWS or a portion thereof or a variant of the given amino acid sequence or portion wherein the side chains of one or two or three or four or five or six or seven of the amino acid residues are altered, wherein the peptide comprising the portion, or variant, is capable of binding HLA-DRB1*03 and/or HLA-DRB1*13,
(FR)
La présente invention concerne un complexe comprenant des molécules HLA classe II-DRB1*03 ou HLA classe II-DRB1*13 liées à un peptide, le peptide comprenant la séquence d'acides aminés HTYTIDWTKDAVTWS ou une partie de celle-ci, ou un variant de la séquence d'acides aminés donnée ou partie de celle-ci, les chaînes latérales d'un, de deux, de trois, de quatre, de cinq, de six ou de sept des résidus d'acides aminés étant modifiées, le peptide qui comprend la partie, ou le variant, étant capable de se lier à HLA-DRB1*03 et/ou HLA-DRB1*13. Le complexe peut être utilisé pour choisir des cellules T spécifiques des antigènes d'Aspergillus et de Candida. Un vaccin contre une infection à Candida albicans comprenant (a) un peptide comprenant la séquence d'acides aminés HTYTIDWTKDAVTWS ou une partie de celle-ci, ou un variant de la séquence d'acides aminés donnée ou partie de celle-ci, les chaînes latérales d'un, de deux, de trois, de quatre, de cinq, de six ou de sept des résidus d'acides aminés étant modifiées, le peptide qui comprend la partie, ou le variant, étant capable de se lier à HLA-DRB1*03 et/ou HLA-DRB1*04 et/ou HLA-DRB1*13, ou (b) un polypeptide qui est une fusion de l'un quelconque des peptides de (a) et d'un autre peptide, ou (c) un polynucléotide codant pour un peptide de (a) ou un polypeptide de (b) ou (d) un vecteur d'expression capable d'exprimer un peptide de (a) ou un polypeptide de (b). Un peptide d'une masse moléculaire inférieure à 10 000 comprenant la séquence d'acides aminés HTYTIDWTKDAVTWS ou une partie de celle-ci ou un variant de la séquence d'acides aminés donnée ou d'une partie de celle-ci, un, deux, trois, quatre, cinq, six ou sept des résidus d'acides aminés étant modifiés, le peptide qui comprend la partie, ou le variant, étant capable de se lier à HLA-DRB1*03 et/ou HLA-DRB1*13.
Latest bibliographic data on file with the International Bureau